重组干扰素γ用于特应性皮炎生物治疗的近期考量
Recent considerations in the use of recombinant interferon gamma for biological therapy of atopic dermatitis.
作者信息
Brar Kanwaljit, Leung Donald Y M
机构信息
a Division of Pediatric Allergy-Immunology, Department of Pediatrics , National Jewish Health , Denver , CO , USA.
b Guangdong Provincial Key Laboratory of Allergy & Clinical Immunology , The State Key Clinical Specialty in Allergy, The Second Affiliated Hospital of Guangzhou Medical University , Guangzhou , China.
出版信息
Expert Opin Biol Ther. 2016;16(4):507-14. doi: 10.1517/14712598.2016.1135898. Epub 2016 Mar 3.
INTRODUCTION
Atopic dermatitis (AD) is the most common inflammatory skin disease in the general population. There are different endophenotypes of AD that likely have a unique immune and molecular basis, such as those who are predisposed to eczema herpeticum, or Staphylococcus aureus infections.
AREAS COVERED
In this review, we highlight the endophenotypes of AD where reduced interferon gamma expression may be playing a role. Additionally, we review the potential role of recombinant interferon gamma therapy in the treatment of atopic dermatitis and the particular phenotypes that may benefit from this treatment.
EXPERT OPINION
Recombinant interferon gamma treatment will likely benefit the pediatric population with AD, as well as those with susceptibilities for skin infections. Future studies are needed to elucidate whether IFN-γ may reduce the prevalence of skin infection in AD.
引言
特应性皮炎（AD）是普通人群中最常见的炎症性皮肤病。AD存在不同的内表型，可能具有独特的免疫和分子基础，例如那些易患疱疹样湿疹或金黄色葡萄球菌感染的患者。
涵盖领域
在本综述中，我们重点关注了干扰素γ表达降低可能起作用的AD内表型。此外，我们回顾了重组干扰素γ治疗在特应性皮炎治疗中的潜在作用以及可能从该治疗中获益的特定表型。
专家观点
重组干扰素γ治疗可能会使患有AD的儿童群体以及那些易患皮肤感染的患者受益。未来需要开展研究以阐明IFN-γ是否可降低AD患者皮肤感染的发生率。
Zotero 插件